WallStSmart

Abbott Laboratories (ABT)vsReWalk Robotics Ltd (LFWD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 215615% more annual revenue ($45.13B vs $20.92M). ABT leads profitability with a 13.9% profit margin vs -123.7%. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

LFWD

Avoid

23

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -18.33
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-28.5%)

Margin of Safety

-28.5%

Fair Value

$70.89

Current Price

$91.07

$20.18 premium

UndervaluedFair: $70.89Overvalued

Intrinsic value data unavailable for LFWD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$151.49B9/10

Large-cap with strong market position

LFWD1 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

LFWD4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$19.71M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.403/10

Elevated debt levels

Return on EquityProfitability
-209.1%2/10

ROE of -209.1% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.30 suggests the stock is reasonably priced for its growth.

Bull Case : LFWD

The strongest argument for LFWD centers on Price/Book.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : LFWD

The primary concerns for LFWD are EPS Growth, Market Cap, Debt/Equity.

Key Dynamics to Monitor

ABT profiles as a value stock while LFWD is a turnaround play — different risk/reward profiles.

ABT carries more volatility with a beta of 0.65 — expect wider price swings.

ABT is growing revenue faster at 7.8% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (56/100 vs 23/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

ReWalk Robotics Ltd

HEALTHCARE · MEDICAL DEVICES · USA

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company is headquartered in Yokneam Illit, Israel.

Want to dig deeper into these stocks?